Villejuif

• PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai … Recruiting
  2025-522108-26-00 4 2026-02-19 métastatique colorectal cancer
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting
  2025-521805-41-00 5 2026-02-18 Patients with HER2-positive, locally advanced or metastatic breast can
• A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adult … Recruiting
  2025-522184-15-00 7 2026-02-18 Advanced Solid Tumor, Metastatic Solid Tumor
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad … Recruiting
  2025-521124-29-00 10 2026-02-13 Non-Small Cell Lung Cancer
• A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC Recruiting
  2025-522914-22-00 3 2026-02-11 Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
• A Phase 1/2 clinical trial of DT-7012 as monotherapy and in combination with an immune checkpoint inhibitor in participants with selected ad … Recruiting
  2025-523758-15-00 7 2026-02-11 Cancer
• A study to assess the safety, tolerability, pharmacokinetic, pharmacodynamic, immunogenicity and antitumour activity of IPN60300 in adults w … Recruiting
  2025-522139-33-00 7 2026-02-10 Advanced or metastatic solid tumours
• A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) Recruiting
  2025-522398-12-00 3 2026-01-30 Locally advanced or metastatic NSCLC
• A first-in-human study to determine a safe dose of the drug TD001 to treat patients with metastatic prostate cancer that expresses the PSMA … Recruiting
  2025-523273-41-00 7 2026-01-30 Metastatic castration-resistant prostate cancer
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Intravenous Mirvetuximab Soravtansin … Recruiting
  2025-521606-18-00 4 2026-01-29 Ovarian Cancer
• Testing two different drugs (sacituzumab-govitecan and trastuzumab-deruxtecan) combinations prescribed in an alterning pattern to patients w … Recruiting
  2025-521909-40-00 4 2026-01-28 Patients with metastatic or locally advanced HER2-low triple-negative
• Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors Recruiting
  2025-521828-30-00 9 2026-01-27 Advanced Solid Tumors
• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af … Recruiting
  2025-522400-24-00 10 2026-01-27 Metastatic urothelial cancer
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Advanced Clear Cell Renal Cell Carcinoma
• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 5 2026-01-21 Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
• FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev … Recruiting
  2023-505781-28-00 4 2026-01-20 Patients with Waldenstrom macroglobulinemia and have received at least
• A Study to test ALE.P03 in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors Recruiting
  2025-521441-24-00 7 2026-01-19 Advanced or Metastatic Solid Tumors
• A Phase 1/2 First-Time-in-Human study of GSK5458514 administered alone or in combination with other anti-cancer agents in participants with … Recruiting
  2025-521581-10-00 7 2026-01-16 Neoplasms, Prostate
• A study to find a suitable dose of ASP5834 in adults with solid tumors Recruiting
  2025-522082-29-00 1 2026-01-16 Locally advanced (unresectable) or metastatic solid tumor malignancies
• NEOREM/NEO-1 - NEOREM: Neo-adjuvant Immunotherapy Master Trial for Localized Cancers / NEO-1: Neo-adjuvant immunotherapy in patients with l … Recruiting
  2025-522127-95-00 4 2026-01-12 NEOREM: Localized solid malignancies that are eligible to receive neo-
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• PULSE : Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including a platinum salt in patie … Recruiting
  2024-514997-27-00 4 2025-12-18 cell penile carcinoma

Showing 193–216 of 978 trials